ElevateBio Announces Appointment Of Ger Brophy, Ph.D., As Interim Chief Executive Officer And New Member Of The Board Of Directors

ElevateBio, a technology-driven company focused on advancing genetic medicines, has announced the appointment of Ger Brophy, Ph.D., as the Interim Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Dr. Brophy succeeds David Hallal, who has transitioned to the role of Executive Chairman of the Board, as previously announced.

Dr. Brophy has been serving as a strategic advisor to ElevateBio's leadership team since May 2024. In this role, he focused on driving growth and expansion across the company’s two main areas: BaseCamp, which handles the end-to-end genetic medicine process development and cGMP manufacturing, and Life Edit, which specializes in gene editing and R&D technology. His advisory work included expanding ElevateBio’s manufacturing capabilities, improving operational efficiency, and helping to establish scalable organizational structures to support the company’s long-term goals.

Dr. Ger Brophy, said in a statement, “I am honored to take on the role of Interim CEO at ElevateBio as we continue to differentiate ourselves through industry-leading expertise and technologies. Our commitment is to support our partners to access and produce new breakthroughs in genetic medicine. Having worked closely with the leadership team over the past year, I've gained a deep appreciation for our integrated approach that unites manufacturing and gene editing capabilities. I'm committed to building on the strong foundation that David and the team have created and to further strengthening our position as the industry leader in powering the next generation of genetic medicines.”

David Hallal, Executive Chairman of ElevateBio, mentioned, “We are fortunate to have someone of Ger's caliber leading ElevateBio over the next year. His vast experience in the life sciences industry and deep understanding of our business gained through his advisory role, combined with his impressive track record of growing businesses and scaling operations, position him well to advance our genetic medicines capabilities.”

Before his role at ElevateBio, Dr. Brophy was the Executive Vice President of BioPharma Production at Avantor, where he remains the Chair of the Scientific Advisory Board. At Avantor, he led the company’s commercial, R&D, production, quality, and regulatory operations, significantly expanding its bioproduction capabilities and global presence. 

Prior to Avantor, Dr. Brophy was Head of Cell Therapy at GE Healthcare Life Sciences (now known as Cytiva), where he played a key role in building and leading the newly established cell therapy manufacturing business. He also served as Chief Technology Officer (CTO) of GE Healthcare Life Sciences, where he was responsible for the company’s R&D portfolio and developed a comprehensive strategy across five newly merged business segments. These experiences make him uniquely qualified to oversee ElevateBio's BaseCamp and Life Edit business units.